Valneva SE
http://www.valneva.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Valneva SE
Evergreen With Envy: Halozyme’s Subcutaneous Conversions Grow As Rivals Hope To Break In
Halozyme’s Enhanze technology has now brought seven monoclonal antibodies, including Ocrevus and Tecentriq, from IV to subcutaneous delivery, but Alteogen and other high-concentration formulation players hope to join the party as Medicare pricing issues help drive interest.
Ipsen Outpaces Market With Lucrative Priority Review Voucher Deal
The going rate to buy a voucher for a faster US FDA application review is about $100m, but the France-headquartered firm received considerably more from an unnamed big pharma.
Another Boost For Valneva and Pfizer Lyme Disease Vaccine
While they wait for the results from their Phase III study, the partners have posted more impressive mid-stage data on what could be the first approved vaccine for a couple of decades to protect against infection from ticks.
Ipsen Outpaces Market With Lucrative Priority Review Voucher Deal
The going rate to buy a voucher that speeds up a regulatory review in the US is about $100m but the France-headquartered firm has managed to get considerably more from an unnamed big pharma.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- BliNK Biomedical SAS
- Crucell Sweden AB
- Iomai Corporation
- Intercell USA, Inc.
- Intercell AG, Vivalis
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice